论文部分内容阅读
目的 探讨肺腺癌组织p16蛋白表达与其预后关系。方法 采用免疫组织化学SP方法观察42例肺腺癌组织p16蛋白的表达情况。结果 ①肺腺癌组织中p16蛋白表达的阳性率为762%,与分化程度和临床分期有关,并随着分化程度的降低而下降,高分化和低分化腺癌之间p16蛋白表达阳性率的差异有显著性(P<001),并且临床分期越高,p16蛋白表达阳性率就越低,Ⅰ期、Ⅱ期肺腺癌p16蛋白表达与Ⅲa期、Ⅲb期比较差异有显著性(P<005)。②肺腺癌组织p16蛋白表达阳性和阴性两组术后3年生存率两组差异有显著性(P<005)。结论 p16蛋白表达缺失与肺癌发生发展有关,并与预后有相关(P<005),检测肺癌组织有无p16蛋白表达可作为判断临床预后的指标。
Objective To investigate the relationship between the expression of p16 protein and prognosis in lung adenocarcinoma. Methods Immunohistochemistry SP method was used to observe the expression of p16 protein in 42 cases of lung adenocarcinoma. Results 1 The positive rate of p16 protein expression in lung adenocarcinoma was 762%, which was related to the degree of differentiation and clinical stage, and decreased with the degree of differentiation. The positive rate of p16 protein expression was positive between well-differentiated and poorly differentiated adenocarcinoma. The difference was significant (P < 001), and the higher the clinical stage, the lower the positive rate of p16 protein expression. The expression of p16 protein in stage I and II lung adenocarcinoma was significantly different from that in stage IIIa and IIIb (P < 005). 2 Positive and negative expression of p16 protein in lung adenocarcinoma tissue The three-year survival rate in the two groups was significantly different (P < 005). Conclusions The loss of p16 protein expression is related to the occurrence and development of lung cancer, and has a correlation with prognosis (P < 005). The detection of p16 protein expression in lung cancer can be used as an index to judge clinical prognosis.